Injectable shear-thinning hydrogels for delivering osteogenic and angiogenic cells and growth factors

Alarçin, Emine; Lee, Tae Yong; Karuthedom, Sobha; Mohammadi, Marzieh; Brennan, Meadhbh Á.; Lee, Dong Hoon; Marrella, Alessandra; Zhang, Jin; Syla, Denata; Zhang, Yu Shrike; Khademhosseini, Ali; Jang, Hae Lin

doi:10.1039/c8bm00293b

Cited by 71 publications

(49 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Their handheld skin bioprinter showed promising capability to be used in large‐scale skin wounds. More recently, Alarçin et al developed a similar handheld system to inject silicate‐based shear‐thinning hydrogels (STHs) encapsulating vasculogenic growth factor‐loaded PCL nanoparticles (Figure E,F) . Through deposition using a multimaterial, single‐nozzle printhead, they were able to bioprint different STHs directly into a bone defect (Figure G).…”

Section: Emerging Evolutions In Bioprintingmentioning

confidence: 99%

3D Bioprinting: from Benches to Translational Applications

Heinrich

Liu

Jimenez

et al. 2019

Small

Self Cite

302

285

View full text Add to dashboard Cite

Over the last decades, the fabrication of 3D tissues has become commonplace in tissue engineering and regenerative medicine. However, conventional 3D biofabrication techniques such as scaffolding, microengineering, and fiber and cell sheet engineering are limited in their capacity to fabricate complex tissue constructs with the required precision and controllability that is needed to replicate biologically relevant tissues. To this end, 3D bioprinting offers great versatility to fabricate biomimetic, volumetric tissues that are structurally and functionally relevant. It enables precise control of the composition, spatial distribution, and architecture of resulting constructs facilitating the recapitulation of the delicate shapes and structures of targeted organs and tissues. This Review systematically covers the history of bioprinting and the most recent advances in instrumentation and methods. It then focuses on the requirements for bioinks and cells to achieve optimal fabrication of biomimetic constructs. Next, emerging evolutions and future directions of bioprinting are discussed, such as freeform, high-resolution, multimaterial, and 4D bioprinting. Finally, the translational potential of bioprinting and bioprinted tissues of various categories are presented and the Review is concluded by exemplifying commercially available bioprinting platforms. BioprintingThe ORCID identification number(s) for the author(s) of this article can be found under https://doi.

show abstract

Section: Emerging Evolutions In Bioprintingmentioning

confidence: 99%

3D Bioprinting: from Benches to Translational Applications

Heinrich

Liu

Jimenez

et al. 2019

Small

Self Cite

302

285

View full text Add to dashboard Cite

show abstract

“…Notably, particle sizes were increased with an increase in drug amount probably due to more viscous aqueous phase based upon high amount of oxaceprol resulted in incomplete dispersion of the phases (Mainardes & Evangelista, ). Zeta potential values of particles were in range between −23 and −21 mV indicating the stability of nanoparticles due to electrostatic repulsion forces which prevent particle aggregation (Alarçin et al., ).…”

Section: Resultsmentioning

confidence: 99%

“…OXC loaded PLGA nanoparticles were fabricated by double‐emulsion (W1/O/W2) solvent evaporation method, described elsewhere, using different amounts of polymer and drug (Alarçin et al., ). Briefly, a 2 ml aqueous internal phase containing 30, 60, or 150 mg OXC was emulsified in a 5 ml methylene chloride solution containing 300 mg PLGA by homogenization (IKA T18 digital ULTRA‐TURRAX, Germany) at 12,000 rpm for 3 min.…”

Section: Methodsmentioning

confidence: 99%

Development and characterization of oxaceprol‐loaded poly‐lactide‐co‐glycolide nanoparticles for the treatment of osteoarthritis

Alarçin

Demirbağ

Karslı-Çeppioğlu

et al. 2020

Drug Development Research

Self Cite

View full text Add to dashboard Cite

Oxaceprol is well-defined therapeutic agent as an atypical inhibitor of inflammation in osteoarthritis. In the present study, we aimed to develop and characterize oxaceprol-loaded poly-lactide-co-glycolide (PLGA) nanoparticles for intra-articular administration in osteoarthritis. PLGA nanoparticles were prepared by doubleemulsion solvent evaporation method. Meanwhile, a straightforward and generally applicable high performance liquid chromatography method was developed, and validated for the first time for the quantification of oxaceprol. To examine the drug carrying capacity of nanoparticles, varying amount of oxaceprol was entrapped into a constant amount of polymer matrix. Moreover, the efficacy of drug amount on nanoparticle characteristics such as particle size, zeta potential, morphology, drug entrapment, and in vitro drug release was investigated. Nanoparticle sizes were between 229 and 509 nm for different amount of oxaceprol with spherical smooth morphology. Encapsulation efficiency ranged between 39.73 and 63.83% by decreasing oxaceprol amount. The results of Fourier transform infrared and DSC showed absence of interaction between oxaceprol and PLGA. The in vitro drug release from these nanoparticles showed a sustained release of oxaceprol over 30 days. According to cell culture studies, oxaceprol-loaded nanoparticles had no cytotoxicity with high biocompatibility. This study was the first step of developing an intra-articular system in the treatment of osteoarthritis for the controlled release of oxaceprol. Our findings showed that these nanoparticles can be beneficial for an effective treatment of osteoarthritis avoiding side effects associated with oral administration. K E Y W O R D Sintra-articular injection, nanoparticle, osteoarthritis, oxaceprol, PLGA

show abstract

“…These devices provide advantages for translation such as user‐friendly designs, low costs and ease of sterilization. Initial work has demonstrated the potential of these handheld direct‐write devices to be used for treatment of chondral injuries, bone nonunions, and skin wounds . The manually operated tools provide the ability to deposit bioinks in these injury sites without the need for expensive, intrusive hardware in the operating room.…”

Section: Advanced 3d Printing Technologiesmentioning

confidence: 99%

Recent Advances in Enabling Technologies in 3D Printing for Precision Medicine

2019

View full text Add to dashboard Cite

Advances in areas such as data analytics, genomics, and imaging have revealed individual patient complexities and exposed the inherent limitations of generic therapies for patient treatment. These observations have also fueled the development of precision medicine approaches, where therapies are tailored for the individual rather than the broad patient population. 3D printing is a field that intersects with precision medicine through the design of precision implants with patient‐directed shapes, structures, and materials or for the development of patient‐specific in vitro models that can be used for screening precision therapeutics. Toward their success, advances in 3D printing and biofabrication technologies are needed with enhanced resolution, complexity, reproducibility, and speed and that encompass a broad range of cells and materials. The overall goal of this progress report is to highlight recent advances in 3D printing technologies that are helping to enable advances important in precision medicine.

show abstract

Injectable shear-thinning hydrogels for delivering osteogenic and angiogenic cells and growth factors

Cited by 71 publications

References 59 publications

3D Bioprinting: from Benches to Translational Applications

3D Bioprinting: from Benches to Translational Applications

Development and characterization of oxaceprol‐loaded poly‐lactide‐co‐glycolide nanoparticles for the treatment of osteoarthritis

Recent Advances in Enabling Technologies in 3D Printing for Precision Medicine

Contact Info

Product

Resources

About